Answers are grounded in this paper and cite their sources.
The interleukin-6/Janus kinase (JAK)/signal transducers and activators of transcription 3 axis is a reported driver of chemotherapy resistance. We hypothesized that adding the JAK1/2 inhibitor ruxolitinib to standard chemotherapy would be tolerable and improve progression-free survival (PFS) in patients with ovarian cancer in the upfront setting.
No takes yet. Share an insight, caveat, or question.
Landen et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: